MedTrace Logo

Interferon Alpha Lozenges Plus Oseltamivir for Influenza Treatment

NCT01146535 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-08-21

No results posted yet for this study

Summary

This study aims to evaluate the safety and effect of interferon-alpha lozenges when used in combination with oseltamivir (Tamiflu) to treat influenza.

Conditions

  • Influenza A Virus Infection

Interventions

DRUG

Interferon-alpha

150 IU lozenges bid for 5 days

DRUG

Oseltamivir

75 mg capsules bid for 5 days

OTHER

maltose

200 mg maltose lozenges bid for 5 days

Sponsors & Collaborators

  • CytoPharm, Inc.

    collaborator INDUSTRY

  • Ainos, Inc. (f/k/a Amarillo Biosciences Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01146535 on ClinicalTrials.gov